55,937 Shares in Bruker Corporation $BRKR Purchased by Squarepoint Ops LLC

Key Points

• Squarepoint Ops acquired 55,937 Bruker shares during the second quarter, worth approximately $3.4 million. Institutional investors collectively own 79.52% of the company’s outstanding stock.
• Bruker reported quarterly EPS of $0.49, beating analyst expectations of $0.38, while revenue rose 5.2% year over year to $838.5 million but fell short of estimates.
• The company declared a quarterly dividend of $0.05 per share, equivalent to a 0.4% yield. Analysts’ consensus rating is Hold, with an average price target of $57 versus the stock’s recent $53.43 price.

Squarepoint Ops LLC acquired a new position in Bruker Corporation (NASDAQ:BRKR - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 55,937 shares of the medical research company's stock, valued at approximately $3,366,000.

Several other large investors have also recently made changes to their positions in the business. Royal Bank of Canada grew its stake in shares of Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock worth $5,148,000 after buying an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Bruker in the first quarter worth $262,000. Goldman Sachs Group Inc. grew its stake in shares of Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock worth $61,162,000 after acquiring an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock worth $15,285,000 after acquiring an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth increased its holdings in shares of Bruker by 115.0% during the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock valued at $469,000 after acquiring an additional 6,008 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Trading Down 0.2%

Bruker stock opened at $53.43 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. Bruker Corporation has a one year low of $30.09 and a one year high of $65.30. The stock has a market capitalization of $8.14 billion, a PE ratio of -76.33, a price-to-earnings-growth ratio of 1.63 and a beta of 1.26. The business's fifty day moving average is $58.25 and its 200 day moving average is $49.25.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker's revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's payout ratio is presently -28.57%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on BRKR shares. Zacks Research cut shares of Bruker from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 2nd. TD Cowen restated a "hold" rating on shares of Bruker in a research note on Wednesday, July 15th. Guggenheim lifted their target price on shares of Bruker from $50.00 to $70.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research note on Wednesday, August 5th. Finally, Citigroup cut their price target on shares of Bruker from $60.00 to $53.00 and set a "hold" rating on the stock in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $57.00.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company's product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.